Wilfred Corredera, MD
Family Medicine · Lake Placid, FLNPI 1891743365
Payments from drug & device makers
Across 304 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$449
- Lilly USA, LLC$337
- Bayer$297
- Johnson & Johnson$262
- GSK$254
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,40796%
- Education$2244%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 105 | $1,645 |
| AstraZeneca(2 entities) | 26 | $449 |
| Lilly USA, LLC | 20 | $337 |
| Bayer | 14 | $297 |
| Johnson & Johnson | 11 | $262 |
| GSK | 16 | $254 |
| Exact Sciences | 11 | $220 |
| Astellas Pharma US Inc | 2 | $200 |
| Amarin Pharma, Inc. | 9 | $191 |
| Corcept Therapeutics | 9 | $188 |
| Regeneron Healthcare Solutions, Inc. | 3 | $161 |
| Novartis | 8 | $135 |
| Xeris Pharmaceuticals, Inc. | 6 | $131 |
| Mannkind Corporation | 6 | $115 |
| Amgen(2 entities) | 6 | $103 |
| Esperion Therapeutics, Inc. | 6 | $99 |
| Pfizer | 6 | $95 |
| Boehringer Ingelheim | 5 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $87 |
| AbbVie(2 entities) | 4 | $81 |
| Dexcom, Inc. | 3 | $64 |
| Sunovion Pharmaceuticals Inc. | 3 | $56 |
| Mylan Specialty L.p. | 3 | $55 |
| Merck | 3 | $52 |
| Lundbeck LLC | 2 | $44 |
| Medtronic | 3 | $38 |
| Eisai Inc. | 1 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Boston Scientific | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Solventum Corporation | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Cequr Corporation | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$121
How this compares
$5,631 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 153 | $227,056 |
| OzempicSemaglutide | 127 | $217,621 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $98,076 |
| JardianceEmpagliflozin | 86 | $97,703 |
| XareltoRivaroxaban | 74 | $97,461 |
| TrulicityDulaglutide | 44 | $92,510 |
| MyrbetriqMirabegron | 65 | $70,825 |
| FarxigaDapagliflozin Propanediol | 53 | $63,138 |
| MounjaroTirzepatide | 45 | $54,689 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $33,368 |
| EntrestoSacubitril/Valsartan | 32 | $32,311 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $28,441 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $23,929 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $22,919 |
| LinzessLinaclotide | 12 | $15,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $95 | $227,056153 claims |
| Novo NordiskOzempic | $1,645 | $217,621127 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $337 | $147,19989 claims |
| Boehringer IngelheimJardiance | $89 | $97,70386 claims |
| Johnson & JohnsonXarelto | $262 | $97,46174 claims |
| Astellas Pharma US IncMyrbetriq | $200 | $70,82565 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $254 | $65,26966 claims |
| AstraZenecaFarxiga | $449 | $63,13853 claims |
| MerckJanumet, Januvia | $52 | $46,78141 claims |
| AbbVieLinzess, Creon, Synthroid | $81 | $32,42766 claims |
| NovartisEntresto | $135 | $32,31132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Lake Placid
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.